top of page
Browse by category
Search
Serotonin plays key role in the development of post-bariatric hypoglycaemia
A study conducted at Harvard University has identified the central role of serotonin - a hormone involved in mood regulation - in the...
LUCIDITY trial to assess Avexitide in post-bariatric hypoglycaemia patients
Amylyx Pharmaceuticals plans to initiate a Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class...
Vogenx announces positive results from second phase 2 study of mizagliflozin in post-bariatric hypoglycaemia
Vogenx has announced positive results from study VGX 001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric...
Last patient receives Mizagliflozin in Phase 2 clinical study for the treatment of post-bariatric hypoglycaemia
Vogenx has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed...
Enrolment complete in Vogenx’ Phase 2 Trial of mizagliflozin for post-bariatric hypoglycaemia
Vogenx has completed patient enrolment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients...
MBX Biosciences gains FDA clearance to study MBX 1416 for post-bariatric hypoglycaemia
MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array...
Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indications
Eiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...
Browse by tag
bottom of page